Astrana Health delivered a strong fourth quarter with revenue growing 43% year-over-year to $950.5 million, driven by significant expansion in its Care Partners segment. Despite a material weakness in internal controls related to acquisition accounting, the company achieved record annual results and provided optimistic 2026 guidance reflecting continued growth from the Prospect Health integration.

Astrana Health delivered robust revenue of 956000000 in Q3 2025, doubling year-over-year, with Care Partners revenue of 897700000. Adjusted EBITDA was 68500000, up 52% YoY, while net income attributable to Astrana was 400000. GAAP EPS was 0.01 per share as the company integrated Prospect Health and continued scaling its platform. :contentReference[oaicite:0]{index=0}

Astrana Health delivered total revenue of 654800000 in Q2 2025, up approximately 35% year-over-year, with net income of 9400000 and adjusted EBITDA of 48100000. EPS was reported at 0.19 per share as the company continued to expand its value-based care operations and integrate the Prospect Health acquisition.

Astrana Health, Inc. reported a strong start to 2025 with total revenue increasing by 53% to $620.4 million. However, net income attributable to Astrana decreased to $6.7 million from $14.8 million in the prior year, and diluted EPS fell to $0.14 from $0.31. Adjusted EBITDA also saw a decrease to $36.4 million from $42.2 million.

Astrana Health, Inc. experienced substantial revenue growth in Q4 2024, with total revenue increasing by 88% year-over-year, primarily driven by a 98% increase in Care Partners revenue; however, the company reported a net loss of $7.0 million for the quarter, compared to a net income in the prior year period.

Astrana Health reported strong third-quarter results driven by the Astrana care model and value-based care enablement platform, demonstrating strong organic and inorganic growth while effectively managing costs and delivering high-quality care. The company is confident in its platform’s ability to improve access, quality, and coordination of care for around 1.1 million patients.

Astrana Health reported strong second quarter results driven by continued organic growth in the Care Partners segment, the successful integration of the Community Family Care acquisition, and continued success in managing total cost of care. The company also entered Arizona and Hawai'i, partnered with Anthem Blue Cross and Elation Health, and agreed to acquire Collaborative Health Systems.

Astrana Health reported a strong first quarter with a 20% increase in revenue, a 13% increase in net income attributable to Astrana, and a 42% increase in adjusted EBITDA compared to the prior year quarter. This performance was primarily driven by solid membership growth across all lines of business and successful management of total cost of care for members. The total number of lives managed increased to approximately one million due to 10% organic membership growth year-to-date.

Astrana Health reported strong Q4 2023 results, highlighting rapid scaling of their care model, robust financial achievements, and continued execution against their strategic roadmap.

Apollo Medical Holdings reported a strong third quarter with a 10% increase in total revenue and a 34% increase in capitated revenue compared to the previous year. The company achieved a 15% adjusted EBITDA margin and narrowed its full-year guidance range. They also announced the intent to acquire assets relating to Community Family Care Medical Group and partnerships with two other provider groups, expanding their value-based care business.

Apollo Medical Holdings, Inc. reported strong second quarter results with a 29% increase in revenue and a 10% increase in net income attributable to ApolloMed. The company reiterated its full-year 2023 guidance.

Apollo Medical Holdings reported a 51% increase in revenue for Q4 2022, reaching $294.2 million. However, the company experienced a net loss attributable to ApolloMed of $2.6 million, compared to a net income of $13.8 million in the prior-year quarter. Adjusted EBITDA increased by 54% to $23.7 million.

ApolloMed reported a 40% increase in revenue to $317.0 million, but net income attributable to AMEH decreased to $26.0 million. The company closed acquisitions of All American Medical Group and Valley Oaks Medical Group in October 2022, and entered into an agreement to acquire For Your Benefit. The company is raising annual guidance for revenue, net income and EBITDA, and reiterating guidance for Adjusted EBITDA.

Apollo Medical Holdings, Inc. reported a strong second quarter in 2022, with a 54% increase in total revenue to $269.7 million. However, net income attributable to ApolloMed decreased to $11.4 million, and EPS-diluted was $0.25. The company is reiterating its full-year guidance for total revenue, net income, EBITDA, and Adjusted EBITDA.

Apollo Medical Holdings reported a 10% increase in total revenue to $195.1 million and a 37% increase in net income to $13.8 million for the fourth quarter of 2021. The company's EPS - diluted increased by 11% to $0.30 per share.

Apollo Medical Holdings, Inc. reported a strong third quarter with a 26% increase in total revenue and a 105% increase in net income attributable to ApolloMed. The company also raised its full-year 2021 guidance due to continued organic growth and increased risk pool settlements and incentives revenue.

Apollo Medical Holdings reported a 6% increase in revenue to $175.6 million and an 80% increase in net income attributable to ApolloMed to $12.7 million for the second quarter of 2021. The company also raised its full-year 2021 guidance due to continued organic growth and encouraging results in the first half of the year.

ApolloMed announced its consolidated financial results for the fourth quarter and year ended December 31, 2020, achieving record top and bottom line growth due to the NGACO's performance, acquisitions, decreased utilization, and increased operational efficiencies.

ApolloMed reported a strong Q3 2020 with a 15% increase in total revenue to $180.1 million and a 137% increase in net income to $25.4 million. Net income attributable to ApolloMed increased to $16.7 million. The company also raised its full-year 2020 net income, EBITDA, and adjusted EBITDA guidance due to a net shared savings settlement of $13.3 million.

ApolloMed reported a strong Q4 2019 with a 68% increase in total revenue to $178.8 million and a net income of $6.7 million, driven by recent acquisitions and preferred dividends. The company manages over one million lives and is focused on scalable and profitable growth.